Cystic Fibrosis sufferers in Ontario are a step closer to an expensive drug treatment paid for by OHIP. Vertex Pharmaceuticals says it has signed a letter of intent with the pan-Canadian Pricing Alliance that will enable public reimbursement of the drug Kalydeco. About 100 Canadian with one of a number of mutations on the CFTR gene, are candidates to use the oral medication which costs more than $300,000 a year per patient. The company says despite the pricing agreement with provincial and territorial governments, it’s up to each province and territory to decide to reimburse the drug through its own drug plan.